Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the publication of new preclinical research in Free Radical Biology and Medicine, highlighting the role of edaravone in mitigating TDP-43 ...

Bain Capital, an investment firm that has spread its life sciences bets mainly across companies developing novel new medicines, is acquiring Mitsubishi Tanabe Pharma Corporation in a multi-billion ...

GV20 Therapeutics (GV20), a clinical-stage AI-powered biotherapeutics company, has entered into a strategic research collaboration with Mitsubishi Tanabe Pharma Corporation (MTPC). Under this ...

TOKYO & BOSTON--(BUSINESS WIRE)--Bain Capital, a leading global private investment firm, today announced it has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation ...

Dewpoint will present two posters at AACRCondensate modulators (c-mods) demonstrate robust anti-tumor effects across multiple types of ...

US investment group Bain Capital has agreed to buy Mitsubishi Tanabe Pharma for JPY 510 billion (around $3.4 billion), setting up one of the largest private equity buyouts in Japan's healthcare ...

Akebia Therapeutics, Inc.’s AKBA share price has dipped by 28.17%, which has investors questioning if this is right time to ...

Akebia Therapeutics, Inc.’s AKBA share price has surged by 11.37%, which has investors questioning if this is right time to ...

Bain Capital has agreed to acquire Mitsubishi Chemical Group’s pharmaceutical business for more than $3 billion, a deal that would allow the Japanese company to focus on its key chemical businesses.

JERSEY CITY, N.J., March 12, 2025 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of eleven abstracts covering research in amyotrophic lateral ...